Future still unclear for cannabis-based medicines after multiple sclerosis trial

The Pharmaceutical Journal Group

首页> 外文期刊>The pharmaceutical journal >Future still unclear for cannabis-based medicines after multiple sclerosis trial

【24h】

Future still unclear for cannabis-based medicines after multiple sclerosis trial

机译：多发性硬化症试验后，基于大麻的药物的未来仍不清楚

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The transformation of Cannabis sativa from illicit drug to medicinal product continues,albeit slowly.In recent years the evidence base to support is use has grown and the prospect of a licensed cannabis-based product is now real.

机译：大麻从非法药物到药用产品的转化仍在继续，尽管进展缓慢。近年来，支持使用的证据基础不断增长，获得许可的基于大麻的产品的前景现在是真实的。

著录项

来源
《The pharmaceutical journal》 |2003年第7275期|共1页
作者
The Pharmaceutical Journal Group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Future still unclear for cannabis-based medicines after multiple sclerosis trial [J] . The Pharmaceutical Journal Group The pharmaceutical journal . 2003,第7275期

机译：多发性硬化症试验后，基于大麻的药物的未来仍不清楚
2. Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis [J] . Herzog Samuel, Shanahan Marian, Grimison Peter, PharmacoEconomics . 2018,第1期

机译：系统审查规定的基于大麻的药物的成本和益处，用于管理慢性疾病的管理：多发性硬化症的课程
3. Cannabis-based medicines in multiple sclerosis--a review of clinical studies. [J] . Rog DJ Immunobiology: Zeitschrift fur Immunitatsforschung . 2010,第8期

机译：多发性硬化症中基于大麻的药物-临床研究综述。
4. Lesion Detection, Segmentation and Prediction in Multiple Sclerosis Clinical Trials [C] . Andrew Doyle, Colm Elliott, Zahra Karimaghaloo, International workshop on brainlesion;International conference on medical imaging computing and computer-assisted intervention . 2018

机译：多发性硬化症临床试验中的病变检测，分割和预测
5. Aging and Disease-modifying Therapies in Multiple Sclerosis: Insights from Clinical Trials and Registries [D] . Zhang, Yinan. 2021

机译：多发性硬化症中的衰老和疾病改性疗法：临床试验和注册管理机构的见解
6. Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach [O] . Stephen Wright, Paul Duncombe, Douglas G Altman 2012

机译：在多发性硬化症患者的基于大麻的药物（Sativex®）研究中评估对治疗分配的盲目性：一种新方法
7. Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach. [O] . Wright, S, Duncombe, P, Altman, DG 2012

机译：在多发性硬化症患者的基于大麻的药物（Sativex®）研究中评估对治疗分配不知情的情况：一种新方法。

Future still unclear for cannabis-based medicines after multiple sclerosis trial

摘要

著录项

相似文献

相关主题

期刊订阅